We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock

Delisted

EVFM was delisted on the 10th of August, 2022.

51 hedge funds and large institutions have $195M invested in Evofem Biosciences, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

21% more funds holding

Funds holding: 4251 (+9)

4% more capital invested

Capital invested by funds: $188M → $195M (+$6.72M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

29% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 17

Holders
51
Holders Change
+9
Holders Change %
+21.43%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
12
Reduced
17
Closed
2
Calls
$585K
Puts
Net Calls
+$585K
Net Calls Change
-$32K
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
51
Federated Hermes
Pennsylvania
-$472K -5,096 Closed
State of Wisconsin Investment Board
52
State of Wisconsin Investment Board
Wisconsin
-$131K -1,420 Closed

EVFM Hedge Fund Activity: Q1 2020 in Review

51 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2020, worth a combined $195M — up 3.6% from $188M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new EVFM positions and 2 closed out — a net gain of 9 holders — while 12 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $38.3M. The largest seller was Schroder Investment Management Group, cutting an estimated $896K.

  • 51 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2020, up from 42 in Q4 2019.
  • Funds reported $195M of Evofem Biosciences, Inc. Common Stock stock for Q1 2020, up 3.6% quarter-over-quarter.
  • 11 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +9 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2020 was BlackRock, an estimated $38.3M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2020 was Schroder Investment Management Group, an estimated $896K sold.

Based on aggregated 13F filings for Q1 2020.